Skip to Content

Grepafloxacin Pregnancy and Breastfeeding Warnings

Grepafloxacin is also known as: Raxar

Grepafloxacin Pregnancy Warnings

Grepafloxacin has been assigned to pregnancy category C. Animal studies have revealed evidence of maternal toxicity, decreases in fetal and placental weight, and in the number of ossified saccrococcygeal vertebrae. Grepafloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

See references

Grepafloxacin Breastfeeding Warnings

Grepafloxacin is excreted into human milk. Because of the potential for serious adverse effects in nursing infants, a decision should be made to discontinue nursing or discontinue administration of the drug, taking into account the importance of the drug to the mother.

Grepafloxacin was detectable in the breast milk of one patient studied on her ninth day of treatment at 4 to 5 hours after oral administration of 400 mg.

Studies using oral radioactive grepafloxacin in lactating rats reported that the concentration of radioactivity observed in the milk was 16 times that observed in the blood.

See references

References for pregnancy information

  1. "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.

References for breastfeeding information

  1. "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide